Calvo Catalá Javier, Campos Fernández Cristina, Rueda Cid Amalia, González-Cruz Cervellera María Isabel, Baixauli Rubio Aurelio, Pastor Cubillo María Dolores
Servicio de Reumatología y Metabolismo Óseo, Consorcio Hospital General Universitario, Valencia, España. calvo
Reumatol Clin. 2011 Jul-Aug;7(4):258-61. doi: 10.1016/j.reuma.2010.10.003. Epub 2011 Feb 18.
Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab.
